AI assistant
CRESCENT BIOPHARMA, INC. — Director's Dealing 2021
Jan 22, 2021
33678_dirs_2021-01-22_60e257be-2a32-4b0a-8163-3582a7b2fde2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2021-01-20
Reporting Person: Thackray Helen M. (SVP Clinical Development, CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-01-20 | Common Stock | A | 34500 | $0.00 | Acquired | 183115 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-20 | Employee Stock Option (right to buy) | $3.81 | A | 69000 | Acquired | 2031-01-19 | Common Stock (69000) | Direct |
Footnotes
F1: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date.
F3: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.